Overall, 38 patients with CD underwent laparoscopic assisted ileo-cecal resection at Schneider Children’s Medical Center of Israel between 2003–2021. Three patients were lost to follow up following surgery and were not included in our cohort (total of 35 patients). The cohort included 19 males (54.2%) and 16 females (45.7%) with a mean age of 15.11 years at time of surgery (range 10.0-17.8). The Mean interval between age at diagnosis and age at surgical intervention was 40.6 months (range 1-110 months, median- 40).
Fourteen patients (40%) required special pre-operative management that took place during admission (pre-operative optimization, such as special enteral or parenteral nutrition, IV antibiotics or intra-abdominal percutaneous abscess drainage. in eight patients, severe fibro-stenotic disease and subsequent imminent obstruction were noted during colonoscopy, that necessitated special enteral and/or parenteral nutrition prior to ICR. In six patients, an intra-abdominal abscess was noted in CT scans, but only half of them (n = 3) necessitated percutaneous or laparoscopic intra-abdominal drainage.
Details regarding pre-operative medical treatment is presented in Table 1.
Table 1: Demographic and pre-operative data:
Characteristics
|
|
|
Gender (M:F)
|
19:16
|
Age at diagnosis of CD (median, range)
|
12.3 (6.0, 17.5)
|
Age at time of ICR (median, range)
|
15.1 (10-17.8)
|
Time from initial diagnosis to surgery in months (range)
|
40.68 (1-110)
|
Pre-operative steroids (n,%)
|
12 (34%)
|
Pre-operative immune-modulators (n,%)
|
11(31.4%)
|
Pre-operative anti TNFa (n,%)
|
21 (60%)
|
Pre-operative enteral or parenteral nutrition (n,%)
|
18 (51.4%)
|
Pre-operative IV antibiotics (n,%)
|
20 (57.14%)
|
Pre- operative intra-abdominal abscess drainage
|
3 (8.57%)
|
All patients underwent laparoscopic assisted ICR with primary anastomosis. 29 patients (82.8%) underwent stapled side to side anastomosis and the remaining 6 patients (17.1%) underwent hand sewn end to end anastomosis.
Mean length of stay following surgery was 8.53 days. There were no post-operative complications, except in a single patient that developed wound infection and required wound exploration. The median follow-up of patients following ICR was 4.7 years. One patient died 15 years following initial surgery due to small bowel adenocarcinoma. Two more patients underwent a second surgical resection, 7 and 10 years following first surgery, respectively, due to active medical-refractory CD.
All patients had close surveillance following ICR by pediatric gastroenterologists and pediatric surgeons. In all patients, a recommendation to start early prophylaxis (immunomodulators in the first years of our study or anti-TNF medications in recent years) was given, and in the past years a follow up colonoscopy was also part of the surveillance, usually in the first year to follow ICR. Median time of follow up was 4.5 years (min – 1 year, max- 16 years).
Clinical recurrence was defined as recurrence of abdominal pain, diarrhea or fever lasting more than 2–3 weeks when an infectious process was ruled out. Out of 35 patients, 18 (51.4%) had recurrent symptoms during the study period, of whom 4 patients demonstrated clinical recurrence in the first two years (11.4%), and 10 patients (28.6%) in the first five years to follow.
Endoscopic recurrence was defined during colonoscopy based on Rutgers score, including anastomotic aphthous lesions, ulcers or diffusely inflamed mucosa, with or without stenosis. In recent years a scheduled colonoscopy was planned in each patient, according to newer protocols. However, in earlier years colonoscopy was performed only after signs of clinical recurrence and/or laboratory results that demonstrated an active inflammatory process. In two patients an endoscopic recurrence was noted, although without clinical recurrence. Details regarding clinical and endoscopic recurrence are outlined in Table 2:
Table 2
Surgical data and post-operative long term follow up:
Characteristic | Clinical recurrence | Endoscopic recurrence |
Recurrence in the 1st year following surgery | 1 | 1 |
Recurrence 1–2 years following surgery | 3 | 5 |
Recurrence 2–5 years following surgery | 6 | 6 |
Recurrence 5–10 years following surgery | 2 | 2 |
Recurrence 10 + years following surgery | 6 | 6 |
Total no. of patients with recurrence | 18 | 16 |
Table 3 outlines risk factors that may be associated with POR. In our cohort, patients that were treated immediately with anti-TNF medications tend to have lower recurrence rate, although not statistically significant. Other factors that were previously reported as risk factors (such as, young age at diagnosis or longer duration to surgery) were not statistically significant, in our cohort, as risk factors of post operative recurrence.
Table 3
– risk factors associated with post operative recurrence:
| No Recurrence (n = 17) | Recurrence (n = 18) | p value |
Age at diagnosis (median, range) | 13 (7, 15.3) | 10 (6, 17.5) | 0.64 |
Time (months) to surgery (median, range) | 27 (1,110) | 43 (3,104) | 0.34 |
Anti-TNFa therapy following initial surgery | 12 | 6 | 0.09 |
Follow up time in Years (average, range) | 4.1 (1–12) | 9.3 (2–16) | 0.14 |